- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
Anybody invested in Geron? Close to being acquired by J&J. UPDATE: STAY AWAY
Posted on 3/13/18 at 9:26 am
Posted on 3/13/18 at 9:26 am
Been holding this patiently for two months and my understanding is the expectation is the company to be acquired by Johnson & Johnson sometime by the 3rd quarter, possibly sooner if their final trial has the positive outcomes folks are expecting.
At $3.18 this AM, up $.28. Earnings this Friday.
In at $2.20. Didn't buy enough to make much a difference unless it doubles. $500 in.
At $3.18 this AM, up $.28. Earnings this Friday.
In at $2.20. Didn't buy enough to make much a difference unless it doubles. $500 in.
This post was edited on 3/28/18 at 9:41 am
8
Posted on 3/15/18 at 9:30 am to YoungManOldMan
Up $.30 this morning. Now at $3.43. I'm in for 219 shares. I'm around 35% return so far.
Posted on 3/15/18 at 9:42 am to YoungManOldMan
Why does every analyst out there have this stock as a sell, reduce, avoid?
Posted on 3/15/18 at 9:48 am to stout
quote:
Why does every analyst out there have this stock as a sell, reduce, avoid?
They're pretty much a one product company for drug Imetelstat for treatment of myelofibrosis. If it fails, they're out of business essentially but the feedback has been positive and the trial results positive as well. Patients are living 2.5-3x's longer on the drug. The anticipation is that if the trial results are positive in April, it's headed for fast track FDA approval and J&J will likely acquire it.
If I were an analyst looking at a single-horse stock, I'm not sure I'd recommend it as well.
Edit: They also think people are going to short the hell out of the stock.
This post was edited on 3/15/18 at 9:54 am
Posted on 3/19/18 at 10:51 am to YoungManOldMan
News came back extremely favorable from this mornings earnings call. Hit a high of $5.15 but has settled back down to about $4.20 this morning consistently.
The outcomes has been favorable and it's still headed down the right track. Study has been expanded to include more patients.
The outcomes has been favorable and it's still headed down the right track. Study has been expanded to include more patients.
Posted on 3/19/18 at 2:32 pm to YoungManOldMan
A therapeutic has about a 10% shot of getting through all 4 phases of approval, and a coin-flip once it gets to stage 3.
Posted on 3/19/18 at 2:34 pm to YoungManOldMan
Never pay attention to the EC when it comes to trials.
Posted on 3/21/18 at 10:37 am to SEC. 593
Up to $4.89 this morning, another 16%.
Who can love you like Geron...nobody...who can give you what you need...nobody.
Who can love you like Geron...nobody...who can give you what you need...nobody.
Posted on 3/21/18 at 6:16 pm to YoungManOldMan
Now at $5.55. This thing has a rocket on it.
Posted on 3/21/18 at 10:25 pm to YoungManOldMan
quote:
In at $2.20. Didn't buy enough to make much a difference unless it doubles. $500 in.
nice pick
Posted on 3/22/18 at 9:42 am to YoungManOldMan
quote:idk, you might be able to retire in a year.
Didn't buy enough to make much a difference unless it doubles. $500 in.
Posted on 3/22/18 at 10:08 am to castorinho
quote:
idk, you might be able to retire in a year.
It has become one of my better calls. I’ve made about $1,000. I dumped today when it hit $6.63. That’s too fast too soon on not much news. I expect it to settle back down around 5 until later in year.
Edit: Back down to mid $5s. Glad I took profits where I could.
This post was edited on 3/22/18 at 10:25 am
Posted on 3/22/18 at 10:27 am to YoungManOldMan
Saw your thread, said screw it and got in at 4.55. Thanks for the 22% gain sir 
:nana:
:nana: Posted on 3/22/18 at 12:37 pm to Sterling Archer
I can't recommend putting any more money into the stock at this point. I pulled out because I think it's hard to believe there will be a larger run up than I experienced the past few days. Most of it I think was just a self feeding frenzy.
It's been up and down all morning but I wouldn't recommend putting any money into it unless you want to keep shorting the stock for $500 gains while putting in $5,000.00 as it pops back and forth $.50.
I'm glad you saw some return.
It's been up and down all morning but I wouldn't recommend putting any money into it unless you want to keep shorting the stock for $500 gains while putting in $5,000.00 as it pops back and forth $.50.
I'm glad you saw some return.
Posted on 3/22/18 at 3:34 pm to YoungManOldMan
I got in and got out, wish I would have got in a lot earlier. But I do really appreciate it
Posted on 3/23/18 at 6:49 pm to Sterling Archer
Did I miss the Gainz?
Posted on 3/28/18 at 9:38 am to theicebox
Stay away from this stock moving forward. Down to $3.92
Seeking Alpha Article Based off Subscription Stat Article
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Geron Corporation
omerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On March 27, 2017, Adam Feuerstein, writing for STAT, published a report stating that the Company's recent stock performance was due to "flimsy" claims with respect to the efficacy of imetelstat, Geron's experimental myelofibrosis treatment. Feuerstein asserted that the available data for imetelstat undercuts Geron's representations as to the drug's efficacy.
On this news, Geron's share price fell $0.83, or 13.88%, to close at $5.15 on March 27, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.
Seeking Alpha Article Based off Subscription Stat Article
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Geron Corporation
omerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On March 27, 2017, Adam Feuerstein, writing for STAT, published a report stating that the Company's recent stock performance was due to "flimsy" claims with respect to the efficacy of imetelstat, Geron's experimental myelofibrosis treatment. Feuerstein asserted that the available data for imetelstat undercuts Geron's representations as to the drug's efficacy.
On this news, Geron's share price fell $0.83, or 13.88%, to close at $5.15 on March 27, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.
This post was edited on 3/28/18 at 9:40 am
Posted on 3/28/18 at 9:04 pm to YoungManOldMan
Time to short?
Posted on 8/24/18 at 9:54 am to YoungManOldMan
Congrats on the sex.
Page 1 of 2
Popular
Back to top
Follow TigerDroppings for LSU Football News